Related Experiment Video

Updated: Aug 15, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

Five-day treatment of non-severe, community-acquired pneumonia with josamycin

J Mensa1, A Trilla, A Moreno

  • 1Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain.

The Journal of Antimicrobial Chemotherapy
|May 1, 1993
PubMed

Insights

Oral josamycin effectively treated community-acquired pneumonia in adults under 60. A five-day course led to rapid fever reduction, normal X-rays, and no relapses, confirming its efficacy.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Community-acquired pneumonia (CAP) is a significant global health concern.
  • Identifying effective and safe antibiotic treatments for non-severe CAP is crucial.
  • Macrolide antibiotics, like josamycin, are commonly used for CAP treatment.

Purpose of the Study:

  • To evaluate the efficacy of oral josamycin as a five-day monotherapy for non-severe community-acquired pneumonia.
  • To assess clinical outcomes, including fever resolution, radiographic findings, and relapse rates.
  • To determine if josamycin is a suitable treatment option for specific patient populations.

Main Methods:

  • An open-label study involving 84 patients (aged <60) with non-severe CAP.
  • Patients received oral josamycin 1g twice daily for five days.
  • Clinical outcomes were assessed, including fever duration, chest X-ray results, and a six-week follow-up for relapses.

Main Results:

  • All 84 patients experienced favorable clinical outcomes.
  • Patients became afebrile within three days, with a mean fever duration of 1.7 days.
  • Chest X-rays were normal post-treatment, and no relapses occurred during follow-up.

Conclusions:

  • A five-day course of oral josamycin is an effective monotherapy for non-severe community-acquired pneumonia.
  • Josamycin demonstrates rapid clinical improvement and a favorable safety profile in this patient group.
  • This regimen offers a viable treatment option for CAP in patients without risk factors for Gram-negative infections.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...